This Article Full Text Full Text (PDF) All Versions of this Article: 200708-1194OCv1 177/2/164    most recent Alert me when this article is cited Alert me if a correction is posted Services Related articles in AJRCCM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Washko, G. R. Search for Related Content PubMed PubMed Citation Articles by Washko, G. R.

The Effect of Lung Volume Reduction Surgery on Chronic Obstructive Pulmonary Disease Exacerbations

¹ Pulmonary and Critical Care Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; ² University of Washington, Seattle, Washington; ³ VA Puget Sound Health Care System, Seattle, Washington; ⁴ Fred Hutchinson Cancer Research Center, Seattle, Washington; ⁵ Cedars-Sinai Medical Center, Los Angeles, California; ⁶ University of Michigan, Ann Arbor, Michigan; ⁷ National Jewish Medical and Research Center, Denver, Colorado; ⁸ University of Pittsburgh, Pittsburgh, Pennsylvania; ⁹ Temple University, Philadelphia, Pennsylvania; ¹⁰ Cleveland Clinic Foundation, Cleveland, Ohio; and ¹¹ Beth Israel Deaconess Medical Center, Boston, Massachusetts

Correspondence and requests for reprints should be addressed to George R. Washko, M.D., Pulmonary and Critical Care Division, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115. E-mail: gwashko{at}partners.org

Rationale: Lung volume reduction surgery (LVRS) has been demonstrated to provide a functional and mortality benefit to a select group of subjects with chronic obstructive pulmonary disease (COPD). The effect of LVRS on COPD exacerbations has not been as extensively studied, and whether improvement in postoperative lung function alters the risk of disease exacerbations is not known.

Objectives: To examine the effect, and mechanism of potential benefit, of LVRS on COPD exacerbations by comparing the medical and surgical cohorts of the National Emphysema Treatment Trial (NETT).

Methods: A COPD exacerbation was defined using Centers for Medicare and Medicaid Services data and International Classification of Diseases, Ninth Revision, discharge diagnosis.

Measurements and Main Results: There was no difference in exacerbation rate or time to first exacerbation between the medical and surgical cohorts during the year before study randomization (P = 0.58 and 0.85, respectively). Postrandomization, the surgical cohort experienced an approximate 30% reduction in exacerbation frequency (P = 0.0005). This effect was greatest in those subjects with the largest postoperative improvement in FEV₁ (P = 0.04) when controlling for changes in other spirometric measures of lung function, lung capacities, and room air arterial blood gas tensions. Finally, LVRS increased the time to first exacerbation in both those subjects with and those without a prior history of exacerbations (P = 0.0002 and P < 0.0001, respectively).

Conclusions: LVRS reduces the frequency of COPD exacerbations and increases the time to first exacerbation. One explanation for this benefit may be the postoperative improvement in lung function.

Clinical trial registered with www.clinicaltrials.gov (NCT 00000606).

Key Words: COPD • LVRS • exacerbation

AT A GLANCE COMMENTARY Scientific Knowledge on the Subject Lung volume reduction surgery (LVRS) offers morbidity and mortality benefits to a subset of people with chronic obstructive pulmonary disease (COPD). Its effect on acute exacerbations is unknown. Improving lung function with LVRS may prevent COPD exacerbations. What This Study Adds to the Field LVRS reduces the frequency of COPD exacerbations and increases the time to first exacerbation. LVRS may decrease the risk of an acute exacerbation through its beneficial effect on lung function.

 

Related articles in AJRCCM:

Acute Exacerbation of Chronic Obstructive Pulmonary Disease: More a Functional than an Inflammatory Problem?

Tobias Welte
AJRCCM 2008 177: 130-131. [Full Text]  

This article has been cited by other articles:

				R. Mann and J. Nichols Management of Chronic Obstructive Pulmonary Disease American Journal of Lifestyle Medicine, November 1, 2009; 3(6): 458 - 465. [Abstract] [PDF]

				W. J. Kim, E. K. Silverman, E. Hoffman, G. J. Criner, Z. Mosenifar, F. C. Sciurba, B. J. Make, V. Carey, R. S. J. Estepar, A. Diaz, et al. CT Metrics of Airway Disease and Emphysema in Severe COPD Chest, August 1, 2009; 136(2): 396 - 404. [Abstract] [Full Text] [PDF]

				A. Anzueto and M. Miravitlles Efficacy of tiotropium in the prevention of exacerbations of COPD Therapeutic Advances in Respiratory Disease, June 1, 2009; 3(3): 103 - 111. [Abstract] [PDF]

				P N Black and C F McDonald Interventions to reduce the frequency of exacerbations of chronic obstructive pulmonary disease Postgrad. Med. J., March 1, 2009; 85(1001): 141 - 147. [Abstract] [Full Text] [PDF]

				K. M. Chan, F. J. Martinez, and A. C. Chang Nonmedical Therapy for Chronic Obstructive Pulmonary Disease Proceedings of the ATS, January 15, 2009; 6(1): 137 - 145. [Abstract] [Full Text] [PDF]

				M. G. Foreman, D. L. DeMeo, C. P. Hersh, V. J. Carey, V. S. Fan, J. J. Reilly, S. D. Shapiro, and E. K. Silverman Polymorphic variation in surfactant protein B is associated with COPD exacerbations Eur. Respir. J., October 1, 2008; 32(4): 938 - 944. [Abstract] [Full Text] [PDF]

				M. Moss, D. Wilkes, and L. B. Ware Clinical Year in Review II: Pulmonary Infections in the Immunocompetent Host, Issues in the Training of Fellows and Residents, Asthma, and Chronic Obstructive Pulmonary Disease Proceedings of the ATS, September 15, 2008; 5(7): 745 - 750. [Full Text] [PDF]

				E. M. Clini and N. Ambrosino Nonpharmacological treatment and relief of symptoms in COPD Eur. Respir. J., July 1, 2008; 32(1): 218 - 228. [Abstract] [Full Text] [PDF]

				T. Welte Acute Exacerbation of Chronic Obstructive Pulmonary Disease: More a Functional than an Inflammatory Problem? Am. J. Respir. Crit. Care Med., January 15, 2008; 177(2): 130 - 131. [Full Text] [PDF]